<PAGE>

                                                                   EXHIBIT 10.11

         **CERTAIN CONFIDENTIAL MATERIAL CONTAINED IN THIS DOCUMENT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO 17 C.F.R. SUBSECTION 200.80(B)(4), 200.83 AND 230.406.**

           AMENDMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT BETWEEN
                            ICN PHARMACEUTICALS. INC.

                                       AND

                              SCHERING-PLOUGH LTD.
                               DATED JULY 28, 1995

                  This Amendment, effective as of the last date below, to the
Exclusive License and Supply Agreement between ICN Pharmaceuticals, Inc. ("ICN")
and Schering-Plough Ltd. ("Schering") dated July 28, 1995 (the "Agreement") is
entered into by and between the parties hereto with reference to the facts
below. Terms with initial capitals which are not specifically defined in this
Amendment shall have the defined meaning set forth in the Agreement.

                  WHEREAS, Section 3.2(c) of the Agreement provides for each
Party to file applications for Regulatory Approval and for Schering to provide
the required information necessary to allow ICN to file for Regulatory Approval
in the EU concurrently with Schering; and

                  WHEREAS, the parties wish to modify the Agreement to provide
for a more orderly process for Regulatory Approval in the EU; and

                  WHEREAS, the parties also wish to modify certain provisions of
the Agreement respecting the supply of product.

                  NOW, THEREFORE, in consideration of the foregoing premises and
the mutual covenants and obligations below, the Parties agree as follows:

                  1.       Section 1.2 of the Agreement shall be modified by
inserting a replacement sentence as the first sentence of that section:

                           "1.2     "Cost of Goods" means the cost to ICN or
                                    Schering, as the case may be, of [REDACTED]
                                    as applicable."
<PAGE>
                  2.       Section 3.2(c) of the Agreement shall be deleted in
its entirety and replaced with the following text:

                           "(c) In the EU, Schering shall be responsible for
                           filing applications for Regulatory Approval in the
                           name of each of the Parties. Schering shall be the
                           contact company for both applications, both at the
                           supra-national (e.g. EMEA) level and the local
                           country level. Schering shall have the responsibility
                           to manage the Regulatory Approval process for each of
                           the applications until all requisite approvals
                           necessary for successful commercialization, including
                           approval for pricing and third party reimbursement
                           approvals, are obtained. Neither Party shall
                           commercially enter the market until the other Party
                           has obtained substantially similar pricing and third
                           party (including applicable government) reimbursement
                           approvals, provided, however, that either Party shall
                           be permitted to enter the market if the other Party
                           chooses to delay market introduction for any other
                           reason."

                  3.       Section 6.4(b) of the Agreement shall be modified by
inserting the following text after the second sentence of that section:

                           "Prior to commercial launch in any country of the
                           Territory, the Estimated Selling Price for that
                           country shall be set at an amount equal to
                           [REDACTED]."

                  4.       Section 8.3(b) of the Agreement shall be modified by
inserting the following text after the first sentence of that section:

                           "However, unless otherwise specified in ICN's written
                           purchase requisition, Schering shall supply Product
                           to ICN in the form of capsules branded and blister
                           packed in cartons with ICN trade dress, labeled in
                           all EU languages and quality-control released in the
                           EU, such that Product so supplied will be suitable
                           for immediate sale to end users in the EU."

                  5.       This Amendment to the Agreement is incorporated
therein and expressly made a part thereof.

                  6.       This Amendment to the extent set forth herein,
amends, modifies and supplements the Agreement. Except as expressly modified
herein, all of the terms and provisions of the Agreement remain in full force
and effect and cannot be amended, modified or changed in any way whatsoever
except by a written instrument duly executed by the Parties hereto.

                                      -2-
<PAGE>
                  IN WITNESS WHEREOF, the Parties have executed this Amendment
effective as of the last date below.


SCHERING-PLOUGH LTD.                        ICN PHARMACEUTICALS, INC.


By:       /s/ David Poorvin                 By:       /s/ David C. Waft
          -------------------------                   --------------------------
          David Poorvin                               David C. Waft

Title:    Prokurist                         Title:    Executive Vice President
                                                      General Counsel &
                                                      Corporate Secretary

Date:     10 December 1997                  Date:     1/20/98
          -------------------------                   --------------------------



                                      -3-